Prevention of Mast Cell Activation Disorder-Associated Clinical Sequelae of Excessive Prostaglandin D2 Production
The DOI matches its Crossref record; 35 of the 36 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with systemic mastocytosis have increased numbers of mast cells in the bone marrow and other organs, such as the liver, spleen, gastrointestinal tract and skin. Symptoms result from the local and remote effects of mediator release from mast cells and from the local effects of increased mast cell numbers in various organs. Patients with mast cell activation experience many of the same clinical symptoms as do patients with systemic mastocytosis from chronic or spontaneous release of mast cell mediators. We report 4 patients with mast cell activation symptoms from selective release of prostaglandin (PG) D(2), but not histamine, and their improvement with aspirin therapy. METHODS: Bone marrow biopsy specimens obtained from 4 patients with symptoms suggestive of mastocytosis were examined by tryptase immunostaining. Baseline levels of serum tryptase and urinary 11beta-PGF(2)(alpha) and N-methylhistamine were obtained. In 2 of the 4 patients, urinary 11beta-PGF(2)(alpha) and N-methylhistamine samples were also measured during acute symptoms. RESULTS: Baseline increase in urinary excretion of the PGD(2) metabolite 11beta-PGF(2)(alpha) was found in 2 patients. In the remaining 2 patients, baseline levels of urinary 11beta-PGF(2)(alpha) and N-methylhistamine were normal, but during acute symptoms, the excretion of 11beta-PGF(2)(alpha) increased markedly. Treatment with aspirin resulted in normalization of 11beta-PGF(2)(alpha) excretion in the 2 patients with elevated baseline levels and in prevention of symptoms in all 4 patients. CONCLUSIONS: These results suggest that mast cell activation may be manifested by a selective excessive release of PGD(2). These patients respond to administration of aspirin but not to antihistamines.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“By contrast, other MC-related markers are less speci fi c and less well (or not yet) validated.”
From Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review (2021) · cites this paper as [46]
In the citing paper
“Prostaglandin D2 (PGD2) is a well-known product of activated MCs.”
From Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review (2021) · cites this paper as [46]
In the citing paper
“limited data are available to establish cutoffs for a signi fi cant increase in the levels of these mediators that would qualify as reliable indicators of severe systemic MCA.”
From Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review (2021) · cites this paper as [46]
In the citing paper
“Mediators other than tryptase are less speci fi c for MCs and MCAS”
From Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review (2021) · cites this paper as [46]
Citations
Cites
Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis
Schwartz, L. B., Metcalfe, D. D., Miller, J. S., Earl, H., & Sullivan, T. (1987) · New England Journal of Medicine · doi:10.1056/nejm198706253162603 · Cited by 784 · cited 1×
“Serum tryptase values have been elevated in samples taken between 1 and 4 h after the precipitating event in 6 of 6 patients seen for anaphylaxis to various triggers [”
BackgroundEpidemiology of anaphylaxis in Olmsted County: A population-based study☆☆☆★★★
Yocum, M. W., Butterfield, J. H., Klein, J. S., Volcheck, G. W., Schroeder, D. R., & Silverstein, M. D. (1999) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(99)70392-1 · Cited by 451
Self-citationIncreased production of prostaglandin D2 in patients with systemic mastocytosis
Roberts, L. J., Sweetman, B. J., Lewis, R. A., Austen, K. F., & Oates, J. A. (1980) · New England Journal of Medicine · doi:10.1056/nejm198012113032405 · Cited by 423
Lin, R. Y., Schwartz, L. B., Curry, A., Pesola, G. R., Knight, R. J., Lee, H.-S., Bakalchuk, L., Tenenbaum, C., & Westfal, R. E. (2000) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2000.107600 · Cited by 277 · cited 1×
“On the basis of our experience with these cases, release of PGD 2 can occur independently of histamine as reflected in the disparate urinary levels of their metabolites. It is possible that excessive release of PGD 2 could be a sign of early mastocytosis before characteristic lesions appear in the bone marrow. No morp…”
BackgroundSheffer, A. L., & Austen, K. F. (1980) · Journal of Allergy and Clinical Immunology · doi:10.1016/0091-6749(80)90056-1 · Cited by 276
Liston, T. E., & Roberts, L. J. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.18.6030 · Cited by 135
Sheffer, A. L., Tong, A. K. F., Murphy, G. F., Lewis, R. A., McFadden, E. R., & Austen, K. F. (1985) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(85)80021-x · Cited by 129
Biphasic systemic anaphylaxis: an inpatient and outpatient study.
Douglas, D. M., Sukenick, E., Andrade, W., & Brown, J. S. (1994) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(94)70044-3 · Cited by 126
Postprandial exercise-induced anaphylaxis
Novey, H. S., Fairshter, R. D., Salness, K., Simon, R. A., & Curd, J. G. (1983) · Journal of Allergy and Clinical Immunology · doi:10.1016/0091-6749(83)90468-2 · Cited by 95
Monitoring mast cell activation by prostaglandin D2 in vivo
Dahlen, S.-E. (2004) · Thorax · doi:10.1136/thx.2004.026641 · Cited by 77
Research works printed but not linked: 1
- 10.1001%2fjama.250.21.2973 · doi:10.1001/jama.250.21.2973
Cited by
Valent, P., Akin, C., Arock, M., Brockow, K., Butterfield, J. H., Carter, M. C., Castells, M., Escribano, L., Hartmann, K., Lieberman, P., et al. (2012) · International Archives of Allergy and Immunology · doi:10.1159/000328760 · Cited by 654
Self-citationAnaphylaxis—a practice parameter update 2015
Lieberman, P., Nicklas, R. A., Randolph, C., Oppenheimer, J., Bernstein, D., Bernstein, J., Ellis, A., Golden, D. B. K., Greenberger, P., Kemp, S., et al. (2015) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2015.07.019 · Cited by 474
Álvarez-Twose, I., González de Olano, D., Sánchez-Muñoz, L., Matito, A., Esteban-López, M. I., Vega, A., Mateo, M. B., Alonso Díaz de Durana, M. D., de la Hoz, B., del Pozo Gil, M. D., et al. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.02.019 · Cited by 294
Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome
Valent, P., Akin, C., Bonadonna, P., Hartmann, K., Brockow, K., Niedoszytko, M., Nedoszytko, B., Siebenhaar, F., Sperr, W. R., Oude Elberink, J. N. G., et al. (2019) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2019.01.006 · Cited by 225
“Likewise, vascular instability may be triggered not only by histamine but also by prostaglandins (PGs) and/or leukotrienes (LTs) derived from activated MCs in the same patient, so that the reaction can be managed when administering histamine receptor blockers and PG/LT synthesis inhibitors and/or receptor blockers.(32…”
BackgroundSelf-citationValent, P., Escribano, L., Broesby‐Olsen, S., Hartmann, K., Grattan, C., Brockow, K., Niedoszytko, M., Nedoszytko, B., Oude Elberink, J. N. G., Kristensen, T., et al. (2014) · Allergy · doi:10.1111/all.12436 · Cited by 174
Self-citationMast cell activation syndrome and mastocytosis: initial treatment options and long-term management
Castells, M., & Butterfield, J. (2019) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2019.02.002 · Cited by 135
Self-citationMast cell activation syndrome: A newly recognized disorder with systemic clinical manifestations
Hamilton, M. J., Hornick, J. L., Akin, C., Castells, M. C., & Greenberger, N. J. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.04.037 · Cited by 132
“Stomach 7 17 (13) 14-28 (5-21) Duodenum 7 23 (27) 18-26 (4-51) Left colon 5 20 (21) 15-27 (10-31) Right colon 4 17 (21) 12-18 (10-31)”
Theoharides, T. C., Tsilioni, I., & Ren, H. (2019) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2019.1596800 · Cited by 120
Weiler, C. R., Austen, K. F., Akin, C., Barkoff, M. S., Bernstein, J. A., Bonadonna, P., Butterfield, J. H., Carter, M., Fox, C. C., Maitland, A., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.08.023 · Cited by 123
Self-citationPardanani, A. (2013) · Blood · doi:10.1182/blood-2013-01-453183 · Cited by 101
Lieberman, P., & Garvey, L. H. (2016) · Current Allergy and Asthma Reports · doi:10.1007/s11882-016-0598-5 · Cited by 102
Gülen, T., Akin, C., Bonadonna, P., Siebenhaar, F., Broesby-Olsen, S., Brockow, K., Niedoszytko, M., Nedoszytko, B., Oude Elberink, H. N. G., Butterfield, J. H., et al. (2021) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2021.06.011 · Cited by 83
“Prostaglandin D2 (PGD2) is a well-known product of activated MCs.(46,49,50,56-59) Studies have shown that during anaphylaxis, as well as in patients with SM, levels of the PGD2 metabolite 9a-11b-PGF2 in urinary samples are elevated compared with healthy controls.”
BackgroundSelf-citationPharmacological treatment options for mast cell activation disease
Molderings, G. J., Haenisch, B., Brettner, S., Homann, J., Menzen, M., Dumoulin, F. L., Panse, J., Butterfield, J., & Afrin, L. B. (2016) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-016-1247-1 · Cited by 79
Self-citationPicard, M., Junior, P. F. G.-B., Mezzano, V., & Castells, M. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.04.001 · Cited by 81
Current treatment options in patients with mastocytosis: status in 2015 and future perspectives
Arock, M., Akin, C., Hermine, O., & Valent, P. (2015) · European Journal Of Haematology · doi:10.1111/ejh.12544 · Cited by 82
Gülen, T., Hägglund, H., Dahlén, B., & Nilsson, G. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12410 · Cited by 75
Molecular Background, Clinical Features and Management of Pediatric Mastocytosis: Status 2021
Lange, M., Hartmann, K., Carter, M. C., Siebenhaar, F., Álvarez‐Twöse, I., Torrado, I., Brockow, K., Renke, J., Irga‐Jaworska, N., Plata‐Nazar, K., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052586 · Cited by 84
Carter, M. C., Metcalfe, D. D., Matito, A., Escribano, L., Butterfield, J. H., Schwartz, L. B., Bonadonna, P., Zanotti, R., Triggiani, M., Castells, M., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.10.063 · Cited by 72
Self-citationRavi, A., Butterfield, J., & Weiler, C. R. (2014) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2014.06.011 · Cited by 63
Self-citationMast cell activation disorders
Akin, C. (2014) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2014.03.007 · Cited by 56
Mast cell activation syndromes: Collegium Internationale Allergologicum update 2022
Valent, P., Hartmann, K., Bonadonna, P., Niedoszytko, M., Triggiani, M., Arock, M., & Brockow, K. (2022) · International Archives of Allergy and Immunology · doi:10.1159/000524532 · Cited by 55
Spectrum of mast cell activation disorders
Petra, A. I., Panagiotidou, S., Stewart, J. M., Conti, P., & Theoharides, T. C. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.906302 · Cited by 54
Factor XII-Driven Inflammatory Reactions with Implications for Anaphylaxis
Bender, L., Weidmann, H., Rose‐John, S., Renné, T., & Long, A. T. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01115 · Cited by 54
Mastocytosis: update on pharmacotherapy and future directions
Cardet, J. C., Akin, C., & Lee, M. J. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.824424 · Cited by 49
Valent, P. (2014) · Clinical & Experimental Allergy · doi:10.1111/cea.12318 · Cited by 47
Doctor, I think I am suffering from MCAS: differential diagnosis and separating facts from fiction
Valent, P., & Akin, C. (2019) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2018.11.045 · Cited by 47
Butterfield, J., & Weiler, C. R. (2020) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2020.02.021 · Cited by 41
Self-citationImmunology and clinical manifestations of non-clonal mast cell activation syndrome
Cardet, J.-C., Castells, M. C., & Hamilton, M. J. (2013) · Current Allergy and Asthma Reports · doi:10.1007/s11882-012-0326-8 · Cited by 39
“Aspirin therapy may be especially useful in carefully selected patients who tolerate NSAIDs and who have persistent flushing and elevated urinary 11βprostaglandin F2 levels [31].”
Lueke, A. J., Meeusen, J. W., Donato, L. J., Gray, A. V., Butterfield, J. H., & Saenger, A. K. (2016) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2016.02.007 · Cited by 40
Self-citationNonclonal Mast Cell Activation Syndrome
Hamilton, M. J. (2018) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2018.04.002 · Cited by 40
Vysniauskaite, M., Hertfelder, H.-J., Oldenburg, J., Dreßen, P., Brettner, S., Homann, J., & Molderings, G. J. (2015) · PLOS ONE · doi:10.1371/journal.pone.0124912 · Cited by 30
Increased Excretion of Mast Cell Mediator Metabolites During Mast Cell Activation Syndrome
Butterfield, J. H. (2023) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2023.02.017 · Cited by 30
Self-citationButterfield, J. H. (2022) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2022.03.008 · Cited by 27
Self-citationSecretory and Membrane-Associated Biomarkers of Mast Cell Activation and Proliferation
Parente, R., Giudice, V., Cardamone, C., Serio, B., Selleri, C., & Triggiani, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087071 · Cited by 27
Hermans, M. A. W., van der Vet, S. Q. A., van Hagen, P. M., van Wijk, R. G., & van Daele, P. L. A. (2018) · Allergy · doi:10.1111/all.13445 · Cited by 28
Using the Right Criteria for MCAS
Gülen, T. (2024) · Current Allergy and Asthma Reports · doi:10.1007/s11882-024-01126-0 · Cited by 24
Pharmacotherapy of mast cell disorders
Gülen, T., & Akin, C. (2017) · Current Opinion in Allergy & Clinical Immunology · doi:10.1097/aci.0000000000000377 · Cited by 21
Systemic Mastocytosis: Clinical Update and Future Directions
Tremblay, D. A., Carreau, N. A., Kremyanskaya, M., & Mascarenhas, J. O. (2015) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2015.07.644 · Cited by 19
Survey of Mast Cell Mediator Levels from Patients Presenting with Symptoms of Mast Cell Activation
Butterfield, J. H. (2019) · International Archives of Allergy and Immunology · doi:10.1159/000503964 · Cited by 17
Self-citationThe difficult management of anaphylaxis in the elderly
González‐de‐Olano, D., Lombardo, C., & Gonzalez-Mancebo, E. (2016) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000280 · Cited by 16
Characterization and modulation of canine mast cell derived eicosanoids
Lin, T., & London, C. A. (2009) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2009.11.010 · Cited by 16
Mast Cell Activation Syndrome Update—A Dermatological Perspective
Mihele, D., Nistor, P., Bruma, G., Mitran, C. I., Mitran, M. I., Condrat, C. E., Țovaru, M., Tampa, M. Ş., & Georgescu, S. R. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13071116 · Cited by 15
Pilkington, S. M., Gibbs, N. K., Costello, P. W., Bennett, S., Massey, K. A., Friedmann, P. S., Nicolaou, A., & Rhodes, L. E. (2016) · Experimental Dermatology · doi:10.1111/exd.13177 · Cited by 15
Management of Mediator Symptoms, Allergy, and Anaphylaxis in Mastocytosis
Gülen, T. (2023) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2023.04.010 · Cited by 14
Diagnosis and Management of Patients With Mast Cell Activation Syndromes: Status 2026
Akin, C., Gülen, T., Castells, M., Elberink, H. O., & Valent, P. (2025) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2025.10.046 · Cited by 15
Mast Cell Activation Syndrome and Gut Dysfunction: Diagnosis and Management
Hamilton, M. J. (2024) · Current Gastroenterology Reports · doi:10.1007/s11894-024-00924-w · Cited by 14
Anaphylaxis: Advances in the Past 10 Years
Weiler, C. R., Schrijvers, R., & Golden, D. B. K. (2022) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2022.09.019 · Cited by 14
Self-citationDrug and Venom Allergy in Mastocytosis
Giannetti, M. P., Nicoloro‐SantaBarbara, J. M., Godwin, G., Middlesworth, J., Espeland, A., & Castells, M. (2023) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2023.04.002 · Cited by 15
Treatment of systemic mastocytosis
Giannetti, M. P. (2021) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2021.06.021 · Cited by 14
Challenges in Drug and Hymenoptera Venom Hypersensitivity Diagnosis and Management in Mastocytosis
Giannetti, M. P., Nicoloro‐SantaBarbara, J. M., Godwin, G., Middlesworth, J., Espeland, A., Douvas, J. L., & Castells, M. (2024) · Diagnostics · doi:10.3390/diagnostics14020123 · Cited by 13
Kaakati, R. N., Khokhar, D. S., & Akin, C. (2024) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2024.10.039 · Cited by 11
Khokhar, D. S., & Akin, C. (2019) · Medical Clinics of North America · doi:10.1016/j.mcna.2019.09.002 · Cited by 14
How to diagnose Mast Cell Activation Syndrome? Practical considerations
Romantowski, J., Górska, A., Lange, M., Nedoszytko, B., Gruchała‐Niedoszytko, M., & Niedoszytko, M. (2020) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.15212 · Cited by 11
Mast Cell Activation Syndromes
Bonamichi-Santos, R., & Castells, M. (2016) · Current Treatment Options in Allergy · doi:10.1007/s40521-016-0100-6 · Cited by 10
Escribano, L., & Orfao, A. (2011) · Anaphylaxis and Hypersensitivity Reactions · doi:10.1007/978-1-60327-951-2_16 · Cited by 7
Childhood Cutaneous Mastocytosis
Swarnkar, B., & Sarkar, R. (2023) · Indian Journal of Dermatology · doi:10.4103/ijd.ijd_264_22 · Cited by 8
Butterfield, J. H., & Singh, R. J. (2021) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2021.106563 · Cited by 8
Self-citationProgress in mast cell activation syndrome: the global consensus-2 diagnostic criteria at six years
Afrin, L. B., Blitshteyn, S., Bluestein, L. S., Dempsey, T. T., Maxwell, A. J., Miller, C. S., Nagy, È., Nugent, D. J., Schofield, J. R., Weinstock, L. B., et al. (2026) · Diagnosis · doi:10.1515/dx-2026-0016 · Cited by 7
Schäfer, D., Dreßen, P., Brettner, S., Rath, N.-F., Molderings, G. J., Jensen, K., & Ziemann, C. (2014) · Journal of Translational Medicine · doi:10.1186/s12967-014-0213-2 · Cited by 7
Butterfield, J. H., & Taylor, A. (2024) · Journal of Allergy and Clinical Immunology Global · doi:10.1016/j.jacig.2024.100399 · Cited by 6
Self-citationLieberman, P. L. (2013) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2013.03.008 · Cited by 6
Generalized pruritus relieved by NSAIDs in the setting of mast cell activation syndrome
Kesterson, K., Nahmias, Z. P., Brestoff, J. R., Bodet, N. D., Kau, A. L., & Kim, B. (2018) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2018.03.002 · Cited by 6
Treatment of patients who present after an episode of anaphylaxis
Lieberman, P. (2013) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2013.06.018 · Cited by 7
Systemic reactions to allergen immunotherapy: A role for measuring a PGD2 metabolite?
Rank, M. A., Kita, H., Li, J. T., & Butterfield, J. H. (2012) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2012.10.009 · Cited by 5
Self-citationButterfield, J. H., & Weiler, C. R. (2013) · International Archives of Allergy and Immunology · doi:10.1159/000356487 · Cited by 5
Self-citationDiagnosis and Treatment of Anaphylaxis in Patients with Mastocytosis
Valent, P., Akin, C., & Arock, M. (2014) · Current Treatment Options in Allergy · doi:10.1007/s40521-014-0021-1 · Cited by 6
The mast cells - Cytokines axis in Autism Spectrum Disorder
Kovacheva, E., Gevezova, M., Maes, M. H. J., & Sarafian, V. S. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.109890 · Cited by 5
Mast cell activation identified through urine mediators
Giannetti, M. P., Godwin, G., Middlesworth, J., Espeland, A., Nicoloro‐SantaBarbara, J. M., & Castells, M. (2024) · Allergy · doi:10.1111/all.16109 · Cited by 4
Types of Hypersensitivities (Updates)
Alkhatib, A. J. (2022) · Springer eBooks · doi:10.1007/978-981-19-1162-0_3 · Cited by 3
Diagnosis and management of mast cell activation syndrome (MCAS) in Canada: a practical approach
Lee, E. Y., & Picard, M. (2025) · Allergy Asthma and Clinical Immunology · doi:10.1186/s13223-025-00998-9 · Cited by 4
Flushing and Urticarial Syndromes Presenting as Anaphylaxis
Butterfield, J. H. (2010) · Humana Press eBooks · doi:10.1007/978-1-60327-951-2_17 · Cited by 2
Self-citationDiagnosis and Laboratory Tests for Anaphylaxis
Cingi, C., & Muluk, N. B. (2019) · Springer eBooks · doi:10.1007/978-3-030-33639-4_6 · Cited by 2
Giannetti, M. P. (2026) · Current Allergy and Asthma Reports · doi:10.1007/s11882-026-01268-3 · Cited by 1
Mast cell activation syndrome — clinical presentation and diagnostic criteria
Boldeanu, E.-S., Avram, M., & Rezmeriţă, L. (2021) · Alergologia · doi:10.26416/aler.5.1.2021.4445 · Cited by 1
Mast Cells and Lipid Mediators
Cho, K. (2016) · Journal of Bacteriology and Virology · doi:10.4167/jbv.2016.46.1.47
The Recurrent Flush: A Case and Review of Systemic Mastocytosis
Mansoor, W., Chugh, S., Hojilla, C. V., Goswami, R. S., & Cavalcanti, R. B. (2018) · Canadian Journal of General Internal Medicine · doi:10.22374/cjgim.v13i2.234
Urinary Markers of Mast Cell Disease and Their Role in Diagnosis and Management
Butterfield, J. H., Pongdee, T., & Ravi, A. (2019) · Springer eBooks · doi:10.1007/978-3-030-27820-5_4
Self-citationIntroduction to Anaphylaxis Essentials
French, S., & Ellis, A. K. (2020) · Springer eBooks · doi:10.1007/978-3-030-43205-8_1
Prise en charge diagnostique et thérapeutique des syndromes d’activation mastocytaire
Clark, E., Schiffmann, A., Jentzer, A., Demoly, P. M., Guilpain, P., & Caimmi, D. P. (2021) · Revue française d'allergologie · doi:10.1016/j.reval.2021.09.002
Arachidonic acid metabolism and its use in the diagnosis of mastocytosis
Jandus, P. (2023) · AIMS Allergy and Immunology · doi:10.3934/allergy.2023006
Gysel, D. V., & Maeseneer, H. D. (2023) · Springer eBooks · doi:10.1007/978-3-031-15130-9_59
Advances in the Management of Mediator-Related Symptoms in Non-Advanced Systemic Mastocytosis
Gülen, T., & Sabato, V. (2026) · ImmunoTargets and Therapy · doi:10.2147/itt.s609692
Metadata
- Authors
- Butterfield, J. H., & Weiler, C. R.
- Affiliations
- Mayo Clinic (US)
- Venue
- International Archives of Allergy and Immunology
- Publisher
- S. Karger AG
- Published
- 2008
- Volume
- 147
- Issue
- 4
- Pages
- 338-343
- ISSN
- 1018-2438 (ISSN-L)
- 1423-0097
- OpenAlex
- W2073764822
- Cited by
- 81
- References
- 36
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 7 · 2023: 7 · 2022: 4 · 2021: 6 · 2020: 3 · 2019: 9 · 2018: 5 · 2017: 2 · 2016: 7 · 2015: 5 · 2014: 7 · 2013: 6 · 2012: 2
- FWCI
- 0.83
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- International Archives of Allergy and Immunology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Mast cells and histamine
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Keywords
- mast cell activation disorders, systemic mastocytosis, prostaglandin D2, aspirin therapy, N-methylhistamine, tryptase, mast cell mediators, symptom prevention
- MeSH terms
- Adult, Anaphylaxis, Aspirin, Female, Histamine Release, Humans, Male, Mast Cells, Mastocytosis, Middle Aged, Prostaglandin D2, Tryptases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.